Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

J Immunol Res. 2021 Sep 9:2021:6439975. doi: 10.1155/2021/6439975. eCollection 2021.

Abstract

In this study, a comprehensive analysis of TNF family members in colorectal cancer (CRC) was conducted and a TNF family-based signature (TFS) was generated to predict prognosis and immunotherapy response. Using the expression data of 516 CRC patients from The Cancer Genome Atlas (TCGA) database, TNF family members were screened to construct a TFS by using the univariate Cox proportional hazards regression and the least absolute shrinkage and selection operator- (LASSO-) Cox proportional hazards regression method. The TFS was then validated in a meta-Gene Expression Omnibus (GEO) cohort (n = 1162) from the GEO database. Additionally, the tumor immune characteristics and predicted responses to immune checkpoint blockade in TFS-based risk subgroups were analyzed. Eight genes (TNFRSF11A, TNFRSF10C, TNFRSF10B, TNFSF11, TNFRSF25, TNFRSF19, LTBR, and NGFR) were used to construct the TFS. Compared to the high-risk patients, the low-risk patients had better overall survival, which was verified by the GEO data. In addition, a high TFS risk score was associated with high infiltration of regulatory T cells (Tregs), nonactivated macrophages (M0), natural killer cells, immune escape phenotypes, poor immunotherapy response, and tumorigenic and metastasis-related pathways. Conversely, a low TFS risk score was related to high infiltration of resting CD4 memory T cells and resting dendritic cells, few immune escape phenotypes, and high sensitivity to immunotherapy. Thus, the eight gene-based TFS is a promising index to predict the prognosis, immune characteristics, and immunotherapy response in CRC, and our results also provide new understanding of the role of the TNF family members in the prognosis and treatment of CRC.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor*
  • Colorectal Neoplasms / diagnosis
  • Colorectal Neoplasms / etiology*
  • Colorectal Neoplasms / mortality*
  • Colorectal Neoplasms / therapy
  • Computational Biology / methods
  • Databases, Genetic
  • Disease Management
  • Disease Susceptibility
  • Female
  • Gene Expression Profiling
  • Gene Ontology
  • Humans
  • Immunotherapy
  • Male
  • Middle Aged
  • Molecular Sequence Annotation
  • Multigene Family*
  • Neoplasm Staging
  • Nomograms
  • Prognosis
  • ROC Curve
  • Transcriptome
  • Treatment Outcome
  • Tumor Microenvironment
  • Tumor Necrosis Factors / genetics*

Substances

  • Biomarkers, Tumor
  • Tumor Necrosis Factors